News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

20/20 GeneSystems, Inc. Licenses Lung Cancer Blood Test to Ortho-Clinical Diagnostics


1/17/2008 9:19:18 AM

ROCKVILLE, Md.--(BUSINESS WIRE)-- 20/20 GeneSystems, Inc. (“20/20”), a developer of innovative diagnostic products for early disease detection and personalized medicine, today announced that it has entered into an agreement with Raritan, N.J., based Ortho-Clinical Diagnostics (“OCD”) to license certain 20/20 intellectual property relating to a blood test for the early detection of lung cancer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES